Kuros Biosciences AG

Swiss Stock Exchange KURN.SW

Kuros Biosciences AG Return on Assets (ROA) for the year ending December 31, 2023: -19.21%

Kuros Biosciences AG Return on Assets (ROA) is -19.21% for the year ending December 31, 2023, a -9.16% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Kuros Biosciences AG Return on Assets (ROA) for the year ending December 31, 2022 was -17.60%, a -113.12% change year over year.
Kuros Biosciences AG Return on Assets (ROA) for the year ending December 31, 2021 was -8.26%, a 32.37% change year over year.
Kuros Biosciences AG Return on Assets (ROA) for the year ending December 31, 2020 was -12.21%, a 4.68% change year over year.
Kuros Biosciences AG Return on Assets (ROA) for the year ending December 31, 2019 was -12.81%, a 6.00% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Swiss Stock Exchange: KURN.SW

Kuros Biosciences AG

CEO	Mr. Christopher T. Fair
IPO Date	Oct. 29, 2002
Location	Switzerland
Headquarters	Wagistrasse 25
Employees	106
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Clinical Trials Composite Materials Petrochemicals Pharmaceuticals Plastics

Description

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

Key trends

Past 5 years